Review



dc2s  (Miltenyi Biotec)


Bioz Verified Symbol Miltenyi Biotec is a verified supplier
Bioz Manufacturer Symbol Miltenyi Biotec manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 95

    Structured Review

    Miltenyi Biotec dc2s
    Ex vivo-generated cDC1s and cDC2s acquire a matured state upon TLR challenge. Enriched cDC1s and cDC2s were overnight stimulated with a maturation cocktail containing R848 and Poly(IC), and the next day, their phenotype and cytokine/chemokine production were characterized. (A) Representative histograms showing the expression levels of CD83, CD40, and CCR7 upon maturation on <t>DC2s</t> (blue histograms) and cDC1s (red histograms). (B) Maturation marker expression on cDC2s (blue dots) and cDC1s (red dots) is displayed as either percentage of positive DCs (CD80, CD86, CD83, CD40, and CCR7) or relative geometric mean fluorescence intensity (gMFI) (HLA-DR). Relative gMFI expression was determined by normalizing to the average gMFI of untreated cDC1s or cDC2s. Scatter dot plots show the mean ± SEM with each data point representing an individual DC donor ( n ≥ 8). (C) Scatter dot plots show the mean ± SEM of the raw concentrations of the indicated cytokines and chemokines. Each data point represents an individual DC donor ( n ≥ 8). Statistical significance was calculated for paired data sets with a paired t-test or a Wilcoxon test, whereas for unpaired data sets significancy was calculated using a Mann–Whitney test. * P < 0.05; ** P < 0.01; *** P < 0.001.
    Dc2s, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 304 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd1c/CD1c+(BDCA-1)+Antibody%2C+anti-human/pmc13336304-91-12-16
    Average 95 stars, based on 304 article reviews
    dc2s - by Bioz Stars, 2026-11
    95/100 stars

    Images

    1) Product Images from "Ex vivo-generated conventional dendritic cells type 1 and type 2 from blood progenitors induce potent antigen-specific T-cell immunity"

    Article Title: Ex vivo-generated conventional dendritic cells type 1 and type 2 from blood progenitors induce potent antigen-specific T-cell immunity

    Journal: Oncoimmunology

    doi: 10.1080/2162402X.2026.2695692

    Ex vivo-generated cDC1s and cDC2s acquire a matured state upon TLR challenge. Enriched cDC1s and cDC2s were overnight stimulated with a maturation cocktail containing R848 and Poly(IC), and the next day, their phenotype and cytokine/chemokine production were characterized. (A) Representative histograms showing the expression levels of CD83, CD40, and CCR7 upon maturation on DC2s (blue histograms) and cDC1s (red histograms). (B) Maturation marker expression on cDC2s (blue dots) and cDC1s (red dots) is displayed as either percentage of positive DCs (CD80, CD86, CD83, CD40, and CCR7) or relative geometric mean fluorescence intensity (gMFI) (HLA-DR). Relative gMFI expression was determined by normalizing to the average gMFI of untreated cDC1s or cDC2s. Scatter dot plots show the mean ± SEM with each data point representing an individual DC donor ( n ≥ 8). (C) Scatter dot plots show the mean ± SEM of the raw concentrations of the indicated cytokines and chemokines. Each data point represents an individual DC donor ( n ≥ 8). Statistical significance was calculated for paired data sets with a paired t-test or a Wilcoxon test, whereas for unpaired data sets significancy was calculated using a Mann–Whitney test. * P < 0.05; ** P < 0.01; *** P < 0.001.
    Figure Legend Snippet: Ex vivo-generated cDC1s and cDC2s acquire a matured state upon TLR challenge. Enriched cDC1s and cDC2s were overnight stimulated with a maturation cocktail containing R848 and Poly(IC), and the next day, their phenotype and cytokine/chemokine production were characterized. (A) Representative histograms showing the expression levels of CD83, CD40, and CCR7 upon maturation on DC2s (blue histograms) and cDC1s (red histograms). (B) Maturation marker expression on cDC2s (blue dots) and cDC1s (red dots) is displayed as either percentage of positive DCs (CD80, CD86, CD83, CD40, and CCR7) or relative geometric mean fluorescence intensity (gMFI) (HLA-DR). Relative gMFI expression was determined by normalizing to the average gMFI of untreated cDC1s or cDC2s. Scatter dot plots show the mean ± SEM with each data point representing an individual DC donor ( n ≥ 8). (C) Scatter dot plots show the mean ± SEM of the raw concentrations of the indicated cytokines and chemokines. Each data point represents an individual DC donor ( n ≥ 8). Statistical significance was calculated for paired data sets with a paired t-test or a Wilcoxon test, whereas for unpaired data sets significancy was calculated using a Mann–Whitney test. * P < 0.05; ** P < 0.01; *** P < 0.001.

    Techniques Used: Ex Vivo, Generated, Expressing, Marker, Fluorescence, MANN-WHITNEY

    Related Articles

    other:

    Article Title: Involvement of autologous myeloid dendritic cells in the evaluation of immediate hypersensitivity reactions to betalactams.
    Article Snippet: Background: Amoxicillin (AX) and clavulanic acid (CLV) are the betalactam antibiotics (BLs) most used to treat bacterial infections, although they can trigger immediate hypersensitivity reactions (IDHRs).. The maturation analysis of monocyte-derived dendritic cells (moDCs) and their capacity to induce proliferative response of lymphocytes are useful to test the sensitisation to a drug, although without optimal sensitivity.. Nevertheless, this can be improved using directly isolated DCs such as myeloid DCs (mDCs).

    Article Title: Antibodies directed against CD127
    Article Snippet: For the ELISA assay, recombinant hCD127 (Sino Biologicals, Beijing, China; reference 10975-H08H) was immobilized on plastic at 1 μg/ml and purified antibody were added to measure binding.

    Article Title: Guidelines for preparation and flow cytometry analysis of human nonlymphoid tissue DC
    Article Snippet: CD1c , PE , AD5‐8E7 , Miltenyi , 130‐110‐536 , 1:100.

    Magnetic Cell Separation:

    Article Title: A biomimetic model composed of injectable 3D muscle-like tissue, stromal and immune cells for recapitulating the rapid immune signature predictive of mRNA vaccine immunogenicity
    Article Snippet: IgG1 or IgG2a isotype controls and monoclonal Abs (mAbs) for HLA-DR (APC-H7, #641411), CD14 (APC, #555399), CD16 (PE, #561313), CD11b (BV750, #747210), CD141 (BDCA3, BV510, #563298), CXCR-3 (PE, #557185), CXCR-4 (PE, #555974), and CD62-L (FITC, #555543) were purchased from BD Biosciences. .. CD11c (PeVio770, #130-113-581), CD1c (BDCA1, FITC, #130-113-301), and CCR7 (PeVio770, #130-117-396) were purchased from MACS from Miltenyi Biotech and CD86 (PE-CF594, #120-869-73) from eBioscience. .. To exclude dead cells from the flow cytometry analyses, Fixable Viability Dye (FvDye, eFluor450, #65-0863-14, eBioscience) was always included in the Ab cocktails.

    Staining:

    Article Title: Decreased levels and function of dendritic cells in blood and airways predict COVID ‐19 severity
    Article Snippet: .. After Live/Dead Blue staining (Invitrogen), cells were incubated with human FcR blocking reagent (Miltenyi Biotec, Bergisch Gladbach, Germany) and then stained with antibodies against surface proteins: CD1c (AD5‐8E7; Miltenyi Biotec), CD3 (SK7; Becton, Dickinson and Company (BD), Franklin Lakes, NJ, USA), CD11c (B‐Ly6; BD), CD14 (M5E2; BD), CD16 (3GE; BioLegend, San Diego, CA, USA), CD19 (HIB19; BioLegend), CD20 (L27; BD), CD45 (HI30; BD), CD56 (HCD56; BD), CD62L (SK11; BD), CD66abce (TET2; Miltenyi Biotec), CD86 (2331; BD), CD123 (7G3; BD), CD141 (AD5‐14H12; Miltenyi Biotec), CCR2 (K036C2; BioLegend), CCR7 (150 503; BD) and HLA‐DR (TU36; Life Technologies, Waltham, MA, USA). .. After Live/Dead Blue staining (Invitrogen), cells were incubated with human FcR blocking reagent (Miltenyi Biotec, Bergisch Gladbach, Germany) and then stained with antibodies against surface proteins: CD1c (AD5‐8E7; Miltenyi Biotec), CD3 (SK7; Becton, Dickinson and Company (BD), Franklin Lakes, NJ, USA), CD11c (B‐Ly6; BD), CD14 (M5E2; BD), CD16 (3GE; BioLegend, San Diego, CA, USA), CD19 (HIB19; BioLegend), CD20 (L27; BD), CD45 (HI30; BD), CD56 (HCD56; BD), CD62L (SK11; BD), CD66abce (TET2; Miltenyi Biotec), CD86 (2331; BD), CD123 (7G3; BD), CD141 (AD5‐14H12; Miltenyi Biotec), CCR2 (K036C2; BioLegend), CCR7 (150 503; BD) and HLA‐DR (TU36; Life Technologies, Waltham, MA, USA).

    Article Title: Decreased levels and function of dendritic cells in blood and airways predict COVID ‐19 severity
    Article Snippet: .. Cells were washed with PBS and stained using Live/Dead Blue (Invitrogen, Thermo Fisher Scientific), incubated with human FcR blocking reagent (Miltenyi Biotec), and stained at 4°C for 20 min with antibodies against the following surface proteins: CD1c (AD5‐8E7; Miltenyi Biotec), CD3 (SK7; BD), CD11c (B‐Ly6; BD), CD14 (M5E2; BD), CD16 (3GE; BioLegend), CD19 (HIB19; BioLegend), CD20 (L27; BD), CD45 (HI30; BD), CD56 (HCD56; BD), CD66abce (TET2; Miltenyi Biotec), CD86 (2331; BD), CD123 (7G3; BD), CD141 (AD5‐14H12; Miltenyi Biotec), and HLA‐DR (TU36; Life Technologies, Thermo Fisher Scientific). .. Cells were washed with PBS and stained using Live/Dead Blue (Invitrogen, Thermo Fisher Scientific), incubated with human FcR blocking reagent (Miltenyi Biotec), and stained at 4°C for 20 min with antibodies against the following surface proteins: CD1c (AD5‐8E7; Miltenyi Biotec), CD3 (SK7; BD), CD11c (B‐Ly6; BD), CD14 (M5E2; BD), CD16 (3GE; BioLegend), CD19 (HIB19; BioLegend), CD20 (L27; BD), CD45 (HI30; BD), CD56 (HCD56; BD), CD66abce (TET2; Miltenyi Biotec), CD86 (2331; BD), CD123 (7G3; BD), CD141 (AD5‐14H12; Miltenyi Biotec), and HLA‐DR (TU36; Life Technologies, Thermo Fisher Scientific).

    Incubation:

    Article Title: Decreased levels and function of dendritic cells in blood and airways predict COVID ‐19 severity
    Article Snippet: .. After Live/Dead Blue staining (Invitrogen), cells were incubated with human FcR blocking reagent (Miltenyi Biotec, Bergisch Gladbach, Germany) and then stained with antibodies against surface proteins: CD1c (AD5‐8E7; Miltenyi Biotec), CD3 (SK7; Becton, Dickinson and Company (BD), Franklin Lakes, NJ, USA), CD11c (B‐Ly6; BD), CD14 (M5E2; BD), CD16 (3GE; BioLegend, San Diego, CA, USA), CD19 (HIB19; BioLegend), CD20 (L27; BD), CD45 (HI30; BD), CD56 (HCD56; BD), CD62L (SK11; BD), CD66abce (TET2; Miltenyi Biotec), CD86 (2331; BD), CD123 (7G3; BD), CD141 (AD5‐14H12; Miltenyi Biotec), CCR2 (K036C2; BioLegend), CCR7 (150 503; BD) and HLA‐DR (TU36; Life Technologies, Waltham, MA, USA). .. After Live/Dead Blue staining (Invitrogen), cells were incubated with human FcR blocking reagent (Miltenyi Biotec, Bergisch Gladbach, Germany) and then stained with antibodies against surface proteins: CD1c (AD5‐8E7; Miltenyi Biotec), CD3 (SK7; Becton, Dickinson and Company (BD), Franklin Lakes, NJ, USA), CD11c (B‐Ly6; BD), CD14 (M5E2; BD), CD16 (3GE; BioLegend, San Diego, CA, USA), CD19 (HIB19; BioLegend), CD20 (L27; BD), CD45 (HI30; BD), CD56 (HCD56; BD), CD62L (SK11; BD), CD66abce (TET2; Miltenyi Biotec), CD86 (2331; BD), CD123 (7G3; BD), CD141 (AD5‐14H12; Miltenyi Biotec), CCR2 (K036C2; BioLegend), CCR7 (150 503; BD) and HLA‐DR (TU36; Life Technologies, Waltham, MA, USA).

    Article Title: Decreased levels and function of dendritic cells in blood and airways predict COVID ‐19 severity
    Article Snippet: .. Cells were washed with PBS and stained using Live/Dead Blue (Invitrogen, Thermo Fisher Scientific), incubated with human FcR blocking reagent (Miltenyi Biotec), and stained at 4°C for 20 min with antibodies against the following surface proteins: CD1c (AD5‐8E7; Miltenyi Biotec), CD3 (SK7; BD), CD11c (B‐Ly6; BD), CD14 (M5E2; BD), CD16 (3GE; BioLegend), CD19 (HIB19; BioLegend), CD20 (L27; BD), CD45 (HI30; BD), CD56 (HCD56; BD), CD66abce (TET2; Miltenyi Biotec), CD86 (2331; BD), CD123 (7G3; BD), CD141 (AD5‐14H12; Miltenyi Biotec), and HLA‐DR (TU36; Life Technologies, Thermo Fisher Scientific). .. Cells were washed with PBS and stained using Live/Dead Blue (Invitrogen, Thermo Fisher Scientific), incubated with human FcR blocking reagent (Miltenyi Biotec), and stained at 4°C for 20 min with antibodies against the following surface proteins: CD1c (AD5‐8E7; Miltenyi Biotec), CD3 (SK7; BD), CD11c (B‐Ly6; BD), CD14 (M5E2; BD), CD16 (3GE; BioLegend), CD19 (HIB19; BioLegend), CD20 (L27; BD), CD45 (HI30; BD), CD56 (HCD56; BD), CD66abce (TET2; Miltenyi Biotec), CD86 (2331; BD), CD123 (7G3; BD), CD141 (AD5‐14H12; Miltenyi Biotec), and HLA‐DR (TU36; Life Technologies, Thermo Fisher Scientific).

    Blocking Assay:

    Article Title: Decreased levels and function of dendritic cells in blood and airways predict COVID ‐19 severity
    Article Snippet: .. After Live/Dead Blue staining (Invitrogen), cells were incubated with human FcR blocking reagent (Miltenyi Biotec, Bergisch Gladbach, Germany) and then stained with antibodies against surface proteins: CD1c (AD5‐8E7; Miltenyi Biotec), CD3 (SK7; Becton, Dickinson and Company (BD), Franklin Lakes, NJ, USA), CD11c (B‐Ly6; BD), CD14 (M5E2; BD), CD16 (3GE; BioLegend, San Diego, CA, USA), CD19 (HIB19; BioLegend), CD20 (L27; BD), CD45 (HI30; BD), CD56 (HCD56; BD), CD62L (SK11; BD), CD66abce (TET2; Miltenyi Biotec), CD86 (2331; BD), CD123 (7G3; BD), CD141 (AD5‐14H12; Miltenyi Biotec), CCR2 (K036C2; BioLegend), CCR7 (150 503; BD) and HLA‐DR (TU36; Life Technologies, Waltham, MA, USA). .. After Live/Dead Blue staining (Invitrogen), cells were incubated with human FcR blocking reagent (Miltenyi Biotec, Bergisch Gladbach, Germany) and then stained with antibodies against surface proteins: CD1c (AD5‐8E7; Miltenyi Biotec), CD3 (SK7; Becton, Dickinson and Company (BD), Franklin Lakes, NJ, USA), CD11c (B‐Ly6; BD), CD14 (M5E2; BD), CD16 (3GE; BioLegend, San Diego, CA, USA), CD19 (HIB19; BioLegend), CD20 (L27; BD), CD45 (HI30; BD), CD56 (HCD56; BD), CD62L (SK11; BD), CD66abce (TET2; Miltenyi Biotec), CD86 (2331; BD), CD123 (7G3; BD), CD141 (AD5‐14H12; Miltenyi Biotec), CCR2 (K036C2; BioLegend), CCR7 (150 503; BD) and HLA‐DR (TU36; Life Technologies, Waltham, MA, USA).

    Article Title: Decreased levels and function of dendritic cells in blood and airways predict COVID ‐19 severity
    Article Snippet: .. Cells were washed with PBS and stained using Live/Dead Blue (Invitrogen, Thermo Fisher Scientific), incubated with human FcR blocking reagent (Miltenyi Biotec), and stained at 4°C for 20 min with antibodies against the following surface proteins: CD1c (AD5‐8E7; Miltenyi Biotec), CD3 (SK7; BD), CD11c (B‐Ly6; BD), CD14 (M5E2; BD), CD16 (3GE; BioLegend), CD19 (HIB19; BioLegend), CD20 (L27; BD), CD45 (HI30; BD), CD56 (HCD56; BD), CD66abce (TET2; Miltenyi Biotec), CD86 (2331; BD), CD123 (7G3; BD), CD141 (AD5‐14H12; Miltenyi Biotec), and HLA‐DR (TU36; Life Technologies, Thermo Fisher Scientific). .. Cells were washed with PBS and stained using Live/Dead Blue (Invitrogen, Thermo Fisher Scientific), incubated with human FcR blocking reagent (Miltenyi Biotec), and stained at 4°C for 20 min with antibodies against the following surface proteins: CD1c (AD5‐8E7; Miltenyi Biotec), CD3 (SK7; BD), CD11c (B‐Ly6; BD), CD14 (M5E2; BD), CD16 (3GE; BioLegend), CD19 (HIB19; BioLegend), CD20 (L27; BD), CD45 (HI30; BD), CD56 (HCD56; BD), CD66abce (TET2; Miltenyi Biotec), CD86 (2331; BD), CD123 (7G3; BD), CD141 (AD5‐14H12; Miltenyi Biotec), and HLA‐DR (TU36; Life Technologies, Thermo Fisher Scientific).

    Isolation:

    Article Title: Loading of STING Agonist into Lipid Nanoparticles Boosts Dendritic Cell Activation
    Article Snippet: DCs were isolated from peripheral blood mononuclear cells (PBMCs) of buffy coats of healthy anonymous donors, provided by the Blood Bank Salzburg as reported previously.44 PBMCs were obtained by gradient density separation with Histopaque-1077 (SigmaAldrich, Austria) and washed three times with PBS before proceeding to subset isolation by magnetic cell separation. .. Conventional type 2 DCs (cDC 2s) were isolated by applying negative selection followed by positive selection using a CD1c (BDCA-1)+ DC isolation kit from Miltenyi Biotec, Germany. .. DCs were isolated from peripheral blood mononuclear cells (PBMCs) of buffy coats of healthy anonymous donors, provided by the Blood Bank Salzburg as reported previously.44 PBMCs were obtained by gradient density separation with Histopaque-1077 (SigmaAldrich, Austria) and washed three times with PBS before proceeding to subset isolation by magnetic cell separation.

    Selection:

    Article Title: Loading of STING Agonist into Lipid Nanoparticles Boosts Dendritic Cell Activation
    Article Snippet: DCs were isolated from peripheral blood mononuclear cells (PBMCs) of buffy coats of healthy anonymous donors, provided by the Blood Bank Salzburg as reported previously.44 PBMCs were obtained by gradient density separation with Histopaque-1077 (SigmaAldrich, Austria) and washed three times with PBS before proceeding to subset isolation by magnetic cell separation. .. Conventional type 2 DCs (cDC 2s) were isolated by applying negative selection followed by positive selection using a CD1c (BDCA-1)+ DC isolation kit from Miltenyi Biotec, Germany. .. DCs were isolated from peripheral blood mononuclear cells (PBMCs) of buffy coats of healthy anonymous donors, provided by the Blood Bank Salzburg as reported previously.44 PBMCs were obtained by gradient density separation with Histopaque-1077 (SigmaAldrich, Austria) and washed three times with PBS before proceeding to subset isolation by magnetic cell separation.



    Similar Products

    95
    Miltenyi Biotec dc2s
    Ex vivo-generated cDC1s and cDC2s acquire a matured state upon TLR challenge. Enriched cDC1s and cDC2s were overnight stimulated with a maturation cocktail containing R848 and Poly(IC), and the next day, their phenotype and cytokine/chemokine production were characterized. (A) Representative histograms showing the expression levels of CD83, CD40, and CCR7 upon maturation on <t>DC2s</t> (blue histograms) and cDC1s (red histograms). (B) Maturation marker expression on cDC2s (blue dots) and cDC1s (red dots) is displayed as either percentage of positive DCs (CD80, CD86, CD83, CD40, and CCR7) or relative geometric mean fluorescence intensity (gMFI) (HLA-DR). Relative gMFI expression was determined by normalizing to the average gMFI of untreated cDC1s or cDC2s. Scatter dot plots show the mean ± SEM with each data point representing an individual DC donor ( n ≥ 8). (C) Scatter dot plots show the mean ± SEM of the raw concentrations of the indicated cytokines and chemokines. Each data point represents an individual DC donor ( n ≥ 8). Statistical significance was calculated for paired data sets with a paired t-test or a Wilcoxon test, whereas for unpaired data sets significancy was calculated using a Mann–Whitney test. * P < 0.05; ** P < 0.01; *** P < 0.001.
    Dc2s, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd1c/CD1c+(BDCA-1)+Antibody%2C+anti-human/pmc13336304-91-12-16
    Average 95 stars, based on 1 article reviews
    dc2s - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    94
    Miltenyi Biotec cd14 microbeads miltenyi biotec
    Ex vivo-generated cDC1s and cDC2s acquire a matured state upon TLR challenge. Enriched cDC1s and cDC2s were overnight stimulated with a maturation cocktail containing R848 and Poly(IC), and the next day, their phenotype and cytokine/chemokine production were characterized. (A) Representative histograms showing the expression levels of CD83, CD40, and CCR7 upon maturation on <t>DC2s</t> (blue histograms) and cDC1s (red histograms). (B) Maturation marker expression on cDC2s (blue dots) and cDC1s (red dots) is displayed as either percentage of positive DCs (CD80, CD86, CD83, CD40, and CCR7) or relative geometric mean fluorescence intensity (gMFI) (HLA-DR). Relative gMFI expression was determined by normalizing to the average gMFI of untreated cDC1s or cDC2s. Scatter dot plots show the mean ± SEM with each data point representing an individual DC donor ( n ≥ 8). (C) Scatter dot plots show the mean ± SEM of the raw concentrations of the indicated cytokines and chemokines. Each data point represents an individual DC donor ( n ≥ 8). Statistical significance was calculated for paired data sets with a paired t-test or a Wilcoxon test, whereas for unpaired data sets significancy was calculated using a Mann–Whitney test. * P < 0.05; ** P < 0.01; *** P < 0.001.
    Cd14 Microbeads Miltenyi Biotec, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd1c/CD1c+(BDCA-1)%2B+Dendritic+Cell+Isolation+Kit%2C+human/10__1016_slash_j__isci__2026__116736-639-174-176
    Average 94 stars, based on 1 article reviews
    cd14 microbeads miltenyi biotec - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    94
    Miltenyi Biotec cd1c isolation kit
    CD34-derived cDC1s and cDC2s can be generated from blood progenitors. CD34-positive cells isolated from blood were differentiated into cDC1s and cDC2s in a 17-day protocol in which progenitors initially expand and afterward undergo skewing towards cDC1 and cDC2 differentiation. (A) Schematic representation of the 17-day protocol for DC generation. (B) Bar graph showing the percentage of cDC1s and cDC2s ± SEM at the end of the culture on day 17 ( n = 10). (C) Representative dot plot showing the presence of cDC1s and cDC2s based on the expression of CD141/CLEC9A and <t>CD1c,</t> respectively, after gating on viable single cells. (D) Violin plot showing the absolute number of cDC1s and cDC2s obtained with the current protocol, depending on the initial amount of cultured CD34-positive cells. Each dot represents the value of expanded cDC1s and cDC2s obtained from one independent donor ( n = 12). (E) Bar graphs show the percentage of positive DCs ± SEM for the given marker ( n = 3). CD34-derived cDC1s and cDC2s were characterized by flow cytometry to determine their lineage marker expression.
    Cd1c Isolation Kit, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd1c/CD1c+(BDCA-1)%2B+Dendritic+Cell+Isolation+Kit%2C+human/pmc13336304-47-12-16
    Average 94 stars, based on 1 article reviews
    cd1c isolation kit - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    86
    Huabio Inc cd1c
    TLS RiskScore association with response to PD-1 blockade and protein-level implementation in FFPE HCC. (A, B) External anti–PD-1-treated HCC cohort: TLS RiskScore by response status (A) and response rates by TLS RiskScore group using the median cutoff (B) . In (B) , colors indicate the within-group proportions of responders and non-responders within each TLS RiskScore group. (C) Spatial transcriptomics mapping canonical TLS-associated chemokines (CXCL13, CCL19, CCL21) and signature signals for regulatory T cells (Treg) and conventional type 2 dendritic cells (cDC2) in representative HCC sections. (D, E) Representative TLS regions in FFPE HCC illustrating cDC2-predominant versus Treg-predominant cellular composition by H&E and multiplex immunofluorescence (mIF) staining (CD11c, <t>CD1c,</t> CD4, FOXP3, CD45, CD21). (F, G) Overall survival (OS) (F) and progression-free survival (PFS) (G) stratified by an mIF-based TLS RiskScore derived from TLS-region Treg (CD4 + FOXP3 + ) and cDC2 (CD11c + CD1c + ) measurements (median cutoff). (H) cDC2 fractions across TLS maturation stages. (I) Treg-to-cDC2 ratio across TLS maturation stages. **P < 0.01 and ****P < 0.0001.
    Cd1c, supplied by Huabio Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd1c/anti+cyclin+d1/pmc13253696-70-20-21
    Average 86 stars, based on 1 article reviews
    cd1c - by Bioz Stars, 2026-11
    86/100 stars
      Buy from Supplier

    94
    Miltenyi Biotec human miltenyi biotec
    TLS RiskScore association with response to PD-1 blockade and protein-level implementation in FFPE HCC. (A, B) External anti–PD-1-treated HCC cohort: TLS RiskScore by response status (A) and response rates by TLS RiskScore group using the median cutoff (B) . In (B) , colors indicate the within-group proportions of responders and non-responders within each TLS RiskScore group. (C) Spatial transcriptomics mapping canonical TLS-associated chemokines (CXCL13, CCL19, CCL21) and signature signals for regulatory T cells (Treg) and conventional type 2 dendritic cells (cDC2) in representative HCC sections. (D, E) Representative TLS regions in FFPE HCC illustrating cDC2-predominant versus Treg-predominant cellular composition by H&E and multiplex immunofluorescence (mIF) staining (CD11c, <t>CD1c,</t> CD4, FOXP3, CD45, CD21). (F, G) Overall survival (OS) (F) and progression-free survival (PFS) (G) stratified by an mIF-based TLS RiskScore derived from TLS-region Treg (CD4 + FOXP3 + ) and cDC2 (CD11c + CD1c + ) measurements (median cutoff). (H) cDC2 fractions across TLS maturation stages. (I) Treg-to-cDC2 ratio across TLS maturation stages. **P < 0.01 and ****P < 0.0001.
    Human Miltenyi Biotec, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd1c/CD1c+(BDCA-1)%2B+Dendritic+Cell+Isolation+Kit%2C+human/pm41997138-350-266-267
    Average 94 stars, based on 1 article reviews
    human miltenyi biotec - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    94
    Cytek Biosciences cflour r668 anti human cd1c
    TLS RiskScore association with response to PD-1 blockade and protein-level implementation in FFPE HCC. (A, B) External anti–PD-1-treated HCC cohort: TLS RiskScore by response status (A) and response rates by TLS RiskScore group using the median cutoff (B) . In (B) , colors indicate the within-group proportions of responders and non-responders within each TLS RiskScore group. (C) Spatial transcriptomics mapping canonical TLS-associated chemokines (CXCL13, CCL19, CCL21) and signature signals for regulatory T cells (Treg) and conventional type 2 dendritic cells (cDC2) in representative HCC sections. (D, E) Representative TLS regions in FFPE HCC illustrating cDC2-predominant versus Treg-predominant cellular composition by H&E and multiplex immunofluorescence (mIF) staining (CD11c, <t>CD1c,</t> CD4, FOXP3, CD45, CD21). (F, G) Overall survival (OS) (F) and progression-free survival (PFS) (G) stratified by an mIF-based TLS RiskScore derived from TLS-region Treg (CD4 + FOXP3 + ) and cDC2 (CD11c + CD1c + ) measurements (median cutoff). (H) cDC2 fractions across TLS maturation stages. (I) Treg-to-cDC2 ratio across TLS maturation stages. **P < 0.01 and ****P < 0.0001.
    Cflour R668 Anti Human Cd1c, supplied by Cytek Biosciences, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd1c/cFluor+R668+Anti-Human+CD1c/pmc12964223-35-0-7
    Average 94 stars, based on 1 article reviews
    cflour r668 anti human cd1c - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    95
    Miltenyi Biotec anti human cd1c bdca1
    TLS RiskScore association with response to PD-1 blockade and protein-level implementation in FFPE HCC. (A, B) External anti–PD-1-treated HCC cohort: TLS RiskScore by response status (A) and response rates by TLS RiskScore group using the median cutoff (B) . In (B) , colors indicate the within-group proportions of responders and non-responders within each TLS RiskScore group. (C) Spatial transcriptomics mapping canonical TLS-associated chemokines (CXCL13, CCL19, CCL21) and signature signals for regulatory T cells (Treg) and conventional type 2 dendritic cells (cDC2) in representative HCC sections. (D, E) Representative TLS regions in FFPE HCC illustrating cDC2-predominant versus Treg-predominant cellular composition by H&E and multiplex immunofluorescence (mIF) staining (CD11c, <t>CD1c,</t> CD4, FOXP3, CD45, CD21). (F, G) Overall survival (OS) (F) and progression-free survival (PFS) (G) stratified by an mIF-based TLS RiskScore derived from TLS-region Treg (CD4 + FOXP3 + ) and cDC2 (CD11c + CD1c + ) measurements (median cutoff). (H) cDC2 fractions across TLS maturation stages. (I) Treg-to-cDC2 ratio across TLS maturation stages. **P < 0.01 and ****P < 0.0001.
    Anti Human Cd1c Bdca1, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd1c/CD1c+(BDCA-1)+Antibody%2C+anti-human/pm41707448-99-118-125
    Average 95 stars, based on 1 article reviews
    anti human cd1c bdca1 - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    94
    Miltenyi Biotec miltenyi biotech cd1c
    TLS RiskScore association with response to PD-1 blockade and protein-level implementation in FFPE HCC. (A, B) External anti–PD-1-treated HCC cohort: TLS RiskScore by response status (A) and response rates by TLS RiskScore group using the median cutoff (B) . In (B) , colors indicate the within-group proportions of responders and non-responders within each TLS RiskScore group. (C) Spatial transcriptomics mapping canonical TLS-associated chemokines (CXCL13, CCL19, CCL21) and signature signals for regulatory T cells (Treg) and conventional type 2 dendritic cells (cDC2) in representative HCC sections. (D, E) Representative TLS regions in FFPE HCC illustrating cDC2-predominant versus Treg-predominant cellular composition by H&E and multiplex immunofluorescence (mIF) staining (CD11c, <t>CD1c,</t> CD4, FOXP3, CD45, CD21). (F, G) Overall survival (OS) (F) and progression-free survival (PFS) (G) stratified by an mIF-based TLS RiskScore derived from TLS-region Treg (CD4 + FOXP3 + ) and cDC2 (CD11c + CD1c + ) measurements (median cutoff). (H) cDC2 fractions across TLS maturation stages. (I) Treg-to-cDC2 ratio across TLS maturation stages. **P < 0.01 and ****P < 0.0001.
    Miltenyi Biotech Cd1c, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd1c/CD1c+(BDCA-1)%2B+Dendritic+Cell+Isolation+Kit%2C+non-human+primate/pm41604686-80-19-19
    Average 94 stars, based on 1 article reviews
    miltenyi biotech cd1c - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    94
    Miltenyi Biotec human cd1c bdca1 dendritic cell isolation kit
    TLS RiskScore association with response to PD-1 blockade and protein-level implementation in FFPE HCC. (A, B) External anti–PD-1-treated HCC cohort: TLS RiskScore by response status (A) and response rates by TLS RiskScore group using the median cutoff (B) . In (B) , colors indicate the within-group proportions of responders and non-responders within each TLS RiskScore group. (C) Spatial transcriptomics mapping canonical TLS-associated chemokines (CXCL13, CCL19, CCL21) and signature signals for regulatory T cells (Treg) and conventional type 2 dendritic cells (cDC2) in representative HCC sections. (D, E) Representative TLS regions in FFPE HCC illustrating cDC2-predominant versus Treg-predominant cellular composition by H&E and multiplex immunofluorescence (mIF) staining (CD11c, <t>CD1c,</t> CD4, FOXP3, CD45, CD21). (F, G) Overall survival (OS) (F) and progression-free survival (PFS) (G) stratified by an mIF-based TLS RiskScore derived from TLS-region Treg (CD4 + FOXP3 + ) and cDC2 (CD11c + CD1c + ) measurements (median cutoff). (H) cDC2 fractions across TLS maturation stages. (I) Treg-to-cDC2 ratio across TLS maturation stages. **P < 0.01 and ****P < 0.0001.
    Human Cd1c Bdca1 Dendritic Cell Isolation Kit, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/cd1c/CD1c+(BDCA-1)%2B+Dendritic+Cell+Isolation+Kit%2C+human/pm41344082-102-8-16
    Average 94 stars, based on 1 article reviews
    human cd1c bdca1 dendritic cell isolation kit - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    Image Search Results


    Ex vivo-generated cDC1s and cDC2s acquire a matured state upon TLR challenge. Enriched cDC1s and cDC2s were overnight stimulated with a maturation cocktail containing R848 and Poly(IC), and the next day, their phenotype and cytokine/chemokine production were characterized. (A) Representative histograms showing the expression levels of CD83, CD40, and CCR7 upon maturation on DC2s (blue histograms) and cDC1s (red histograms). (B) Maturation marker expression on cDC2s (blue dots) and cDC1s (red dots) is displayed as either percentage of positive DCs (CD80, CD86, CD83, CD40, and CCR7) or relative geometric mean fluorescence intensity (gMFI) (HLA-DR). Relative gMFI expression was determined by normalizing to the average gMFI of untreated cDC1s or cDC2s. Scatter dot plots show the mean ± SEM with each data point representing an individual DC donor ( n ≥ 8). (C) Scatter dot plots show the mean ± SEM of the raw concentrations of the indicated cytokines and chemokines. Each data point represents an individual DC donor ( n ≥ 8). Statistical significance was calculated for paired data sets with a paired t-test or a Wilcoxon test, whereas for unpaired data sets significancy was calculated using a Mann–Whitney test. * P < 0.05; ** P < 0.01; *** P < 0.001.

    Journal: Oncoimmunology

    Article Title: Ex vivo-generated conventional dendritic cells type 1 and type 2 from blood progenitors induce potent antigen-specific T-cell immunity

    doi: 10.1080/2162402X.2026.2695692

    Figure Lengend Snippet: Ex vivo-generated cDC1s and cDC2s acquire a matured state upon TLR challenge. Enriched cDC1s and cDC2s were overnight stimulated with a maturation cocktail containing R848 and Poly(IC), and the next day, their phenotype and cytokine/chemokine production were characterized. (A) Representative histograms showing the expression levels of CD83, CD40, and CCR7 upon maturation on DC2s (blue histograms) and cDC1s (red histograms). (B) Maturation marker expression on cDC2s (blue dots) and cDC1s (red dots) is displayed as either percentage of positive DCs (CD80, CD86, CD83, CD40, and CCR7) or relative geometric mean fluorescence intensity (gMFI) (HLA-DR). Relative gMFI expression was determined by normalizing to the average gMFI of untreated cDC1s or cDC2s. Scatter dot plots show the mean ± SEM with each data point representing an individual DC donor ( n ≥ 8). (C) Scatter dot plots show the mean ± SEM of the raw concentrations of the indicated cytokines and chemokines. Each data point represents an individual DC donor ( n ≥ 8). Statistical significance was calculated for paired data sets with a paired t-test or a Wilcoxon test, whereas for unpaired data sets significancy was calculated using a Mann–Whitney test. * P < 0.05; ** P < 0.01; *** P < 0.001.

    Article Snippet: After 2 h of coculture at 37oC, cells were stained to identify DC2s (CD1c-FITC, 1:25, 130-113-301, Miltenyi Biotec) and cDC1s (CD141 PerCP-Cy5.5, 1:25, 344112, BioLegend) prior to analysis using a BD FACSLyricTM.

    Techniques: Ex Vivo, Generated, Expressing, Marker, Fluorescence, MANN-WHITNEY

    CD34-derived cDC1s and cDC2s can be generated from blood progenitors. CD34-positive cells isolated from blood were differentiated into cDC1s and cDC2s in a 17-day protocol in which progenitors initially expand and afterward undergo skewing towards cDC1 and cDC2 differentiation. (A) Schematic representation of the 17-day protocol for DC generation. (B) Bar graph showing the percentage of cDC1s and cDC2s ± SEM at the end of the culture on day 17 ( n = 10). (C) Representative dot plot showing the presence of cDC1s and cDC2s based on the expression of CD141/CLEC9A and CD1c, respectively, after gating on viable single cells. (D) Violin plot showing the absolute number of cDC1s and cDC2s obtained with the current protocol, depending on the initial amount of cultured CD34-positive cells. Each dot represents the value of expanded cDC1s and cDC2s obtained from one independent donor ( n = 12). (E) Bar graphs show the percentage of positive DCs ± SEM for the given marker ( n = 3). CD34-derived cDC1s and cDC2s were characterized by flow cytometry to determine their lineage marker expression.

    Journal: Oncoimmunology

    Article Title: Ex vivo-generated conventional dendritic cells type 1 and type 2 from blood progenitors induce potent antigen-specific T-cell immunity

    doi: 10.1080/2162402X.2026.2695692

    Figure Lengend Snippet: CD34-derived cDC1s and cDC2s can be generated from blood progenitors. CD34-positive cells isolated from blood were differentiated into cDC1s and cDC2s in a 17-day protocol in which progenitors initially expand and afterward undergo skewing towards cDC1 and cDC2 differentiation. (A) Schematic representation of the 17-day protocol for DC generation. (B) Bar graph showing the percentage of cDC1s and cDC2s ± SEM at the end of the culture on day 17 ( n = 10). (C) Representative dot plot showing the presence of cDC1s and cDC2s based on the expression of CD141/CLEC9A and CD1c, respectively, after gating on viable single cells. (D) Violin plot showing the absolute number of cDC1s and cDC2s obtained with the current protocol, depending on the initial amount of cultured CD34-positive cells. Each dot represents the value of expanded cDC1s and cDC2s obtained from one independent donor ( n = 12). (E) Bar graphs show the percentage of positive DCs ± SEM for the given marker ( n = 3). CD34-derived cDC1s and cDC2s were characterized by flow cytometry to determine their lineage marker expression.

    Article Snippet: Alternatively, DCs were enriched by MACS using CD141-Microbeads (130-090-512, Miltenyi Biotec) and CD1c Isolation kit (130-119-475, Miltenyi Biotec) sequentially (see supplementary figure 1C).

    Techniques: Derivative Assay, Generated, Isolation, Expressing, Cell Culture, Marker, Flow Cytometry

    TLS RiskScore association with response to PD-1 blockade and protein-level implementation in FFPE HCC. (A, B) External anti–PD-1-treated HCC cohort: TLS RiskScore by response status (A) and response rates by TLS RiskScore group using the median cutoff (B) . In (B) , colors indicate the within-group proportions of responders and non-responders within each TLS RiskScore group. (C) Spatial transcriptomics mapping canonical TLS-associated chemokines (CXCL13, CCL19, CCL21) and signature signals for regulatory T cells (Treg) and conventional type 2 dendritic cells (cDC2) in representative HCC sections. (D, E) Representative TLS regions in FFPE HCC illustrating cDC2-predominant versus Treg-predominant cellular composition by H&E and multiplex immunofluorescence (mIF) staining (CD11c, CD1c, CD4, FOXP3, CD45, CD21). (F, G) Overall survival (OS) (F) and progression-free survival (PFS) (G) stratified by an mIF-based TLS RiskScore derived from TLS-region Treg (CD4 + FOXP3 + ) and cDC2 (CD11c + CD1c + ) measurements (median cutoff). (H) cDC2 fractions across TLS maturation stages. (I) Treg-to-cDC2 ratio across TLS maturation stages. **P < 0.01 and ****P < 0.0001.

    Journal: Frontiers in Immunology

    Article Title: Tumor immune microenvironment states inferred from TLS-associated immune-cell composition stratify prognosis in hepatocellular carcinoma

    doi: 10.3389/fimmu.2026.1818138

    Figure Lengend Snippet: TLS RiskScore association with response to PD-1 blockade and protein-level implementation in FFPE HCC. (A, B) External anti–PD-1-treated HCC cohort: TLS RiskScore by response status (A) and response rates by TLS RiskScore group using the median cutoff (B) . In (B) , colors indicate the within-group proportions of responders and non-responders within each TLS RiskScore group. (C) Spatial transcriptomics mapping canonical TLS-associated chemokines (CXCL13, CCL19, CCL21) and signature signals for regulatory T cells (Treg) and conventional type 2 dendritic cells (cDC2) in representative HCC sections. (D, E) Representative TLS regions in FFPE HCC illustrating cDC2-predominant versus Treg-predominant cellular composition by H&E and multiplex immunofluorescence (mIF) staining (CD11c, CD1c, CD4, FOXP3, CD45, CD21). (F, G) Overall survival (OS) (F) and progression-free survival (PFS) (G) stratified by an mIF-based TLS RiskScore derived from TLS-region Treg (CD4 + FOXP3 + ) and cDC2 (CD11c + CD1c + ) measurements (median cutoff). (H) cDC2 fractions across TLS maturation stages. (I) Treg-to-cDC2 ratio across TLS maturation stages. **P < 0.01 and ****P < 0.0001.

    Article Snippet: The antibody panel included CD45 (Aifang, AF20018), CD4 (Aifang, AF20210), FOXP3 (Maxim, MAB-1004), CD11c (Aifang, AF20381), CD21 (Aifang, AF20013), and CD1c (HUABIO, HA722562), each used at 1:200.

    Techniques: Spatial Transcriptomics, Multiplex Assay, Immunofluorescence, Staining, Derivative Assay